Company intelligence / Profile preview

Rendiatech

Israel

Ownership: Private
Development stage: Other

Overview

Rendiatech has developed FDA-cleared technology for continuous monitoring of urine flow and acute kidney injury detection. The Clarity RMS system is already commercially available as a critical care monitoring system that continuously measures urine output and sends real-time alerts to medical staff. The company is developing a next-generation system called Clarity Prime to further advance urine monitoring capabilities.

Therapeutic areas: NephrologyMetabolic Disorders
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Nuwellis (proposed acquisition as of December 2025)

Beyond the preview

Go deeper on Rendiatech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rendiatech.

Explore the full profile